Immunosuppressant shows promise in managing inflammation in birdshot retinochoroidopathy

Infliximab managed inflammation in patients with treatment-refractory birdshot retinochoroidopathy, according to a study.Forty-four eyes of 22 patients with refractory birdshot retinochoroidopathy received 4 mg/kg to 5 mg/kg of infliximab at intervals of 4 to 8 weeks. All patients underwent prior unsuccessful conventional immunosuppressive therapy.

Full Story →